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OBJECTIVE: To study the efficacy, safety, and acceptabil-
ity of oral immediately swallowed and buccal misopros-
tol 800 mcg after mifepristone 200 mg for terminating
pregnancy through 63 days since the last menstrual
period (LMP).
METHODS: This seven-site study randomly assigned 966
women seeking abortions to oral or buccal misoprostol
800 mcg 24–36 hours after mifepristone 200 mg with
7–14-day follow-up.
RESULTS: Success rates in the oral and buccal groups
were 91.3% (389 of 426) and 96.2% (405 of 421), respec-
tively (P.003; relative risk [RR] 0.95, 95% confidence
interval [CI] 0.92–0.98). Ongoing pregnancy occurred in
3.5% (15 of 426) of women who took oral misoprostol
compared with 1.0% (4 of 421) of women in the buccal
group (P.012; RR 3.71, 95% CI 1.24–11.07). Through 49
days since the LMP, oral and buccal regimens performed
similarly, but success with oral misoprostol decreased as
pregnancy advanced. In pregnancies of 57–63 days since
the LMP, success with oral misoprostol fell below 90%,
whereas that with buccal remained high (oral 85.1% [97
of 114], buccal 94.8% [109 of 115], P.015, RR 0.90, 95%
CI 0.82–0.98). Furthermore, in this gestational age group,
there were significantly more ongoing pregnancies
among women who took misoprostol orally (7.9% [9 of
114]) compared with buccally (1.7% [2 of 115]; P.029,
RR 4.54, 95% CI 1.0–20.55). Adverse effect profiles were
similar, although fever and chills were reported approx-
imately 10% more often among women who took buccal
misoprostol. Satisfaction and acceptability were high for
both methods.
CONCLUSION: Buccal misoprostol 800 mcg after mife-
pristone 200 mg is a good option for medical abortion
through 63 days since the LMP. Oral misoprostol 800 mcg
is also a safe and effective alternative, although success
rates diminish with increasing gestational age.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.
clinicaltrials.gov, NCT00386867
(Obstet Gynecol 2008;112:1303–10)
LEVEL OF EVIDENCE: I
After mifepristone was approved by the UnitedStates Food and Drug Administration in 2000,
vaginal use of misoprostol 800 mcg became almost a
standard of care in early medical abortion.1–3 How-
ever, nonvaginal routes of misoprostol administration
are now of increasing interest to women and provid-
ers because of 1) lower acceptability of vaginal admin-
istration4,5; 2) legal peril to women where abortion is
clandestine and pill remnants may remain in the
vagina; and 3) concern about infection, specifically,
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very rare but fatal clostridial infections6,7 (although no
association between such infections and use of vaginal
misoprostol has been found). In March 2006, Planned
Parenthood Federation of America changed its na-
tional guidelines to avoid vaginal administration of
misoprostol, but the scanty evidence supporting a
nonvaginal regimen through 63 days since the last
menstrual period (LMP) meant that medical abortion
was no longer an option for women with pregnancies
of more than 56 days since the LMP.
Oral (immediately swallowing pills), buccal
(holding pills in the cheek) and sublingual (holding
pills under the tongue) misoprostol administration
after mifepristone has been studied as an alternative
to vaginal administration in early medical abortion.
Encouraging but equivocal findings of studies on 800
mcg oral misoprostol8–10 and unpublished claims of
high clinical success and tolerance of adverse effects
with this regimen in a large United Kingdom system
( January 2006, Dr. Kate Worsley, personal commu-
nication) suggested the need for a more definitive
trial. Similarly, because an 800 mcg buccal regimen
had been shown to be as effective as a 800 mcg
vaginal regimen through 56 days since the LMP11 and
the pharmacokinetic profiles and effect on uterine
contractility were similar,12,13 we decided that buccal
administration was also a likely candidate for use
through 63 days since the LMP. We conducted a
randomized trial to explore whether 800 mcg oral and
buccal misoprostol 24–36 hours after mifepristone
200 mg are effective regimens for routine clinical use
in medical abortion through 63 days since the LMP.
MATERIALS AND METHODS
We report an open-label, randomized trial to charac-
terize oral and buccal misoprostol administration after
mifepristone in women with pregnancies through 63
days since the LMP. The study was implemented in
seven facilities in the United States: Family Planning
Associates Medical Group (Chicago); Institute of Ur-
ban Family Health (New York); Magee Womens
Hospital/University of Pittsburgh (Pittsburgh); Parkmed
(New York); Planned Parenthood League of Massachu-
setts (Boston); Planned Parenthood of Waco (Waco);
and Whole Woman’s Health (Austin). The Western
Institutional Review Board and the institutional review
boards at the University of Pittsburgh and the Institute
for Urban Family Health approved the protocol.
Women seeking medical abortion were eligible if
they did not have U.S. Food and Drug Administra-
tion–labeled contraindications to the method, were at
least 18 years old, and had an intrauterine pregnancy
not exceeding 63 days since the LMP on the day of
the medical abortion. Gestational age was determined
by LMP, clinical examination, and/or ultrasonogra-
phy, as needed. Participants had to be willing and
able to sign consent forms, have access to a telephone
and emergency transportation, speak and read En-
glish or Spanish, and agree to comply with the study
procedures. Screening and enrollment generally oc-
curred during the same visit, except when state-
mandated 24-hour waiting periods after informed
consent required a second visit.
On day 1, participants swallowed mifepristone
200 mg (Mifeprex; Danco Laboratories, New York,
NY) in the clinic and then were provided with
misoprostol 800 mcg (Ivax Pharmaceuticals, Miami,
FL) to take 24–36 hours later at home, either orally or
buccally according to random assignment. Women
assigned to take misoprostol buccally were instructed
to hold two 200-mcg pills in each cheek pouch for 30
minutes and then to swallow any remnants. Women
were offered prescriptions for oral narcotics to man-
age pain and antidiarrheal and antinausea medica-
tions, according to local standards at each facility.
Participants maintained a diary for up to 15 days to
record misoprostol administration, pain, bleeding,
adverse effects and medications taken.
Participants returned to the study site 7 to14 days
after taking mifepristone for clinical assessment, in-
cluding transvaginal ultrasonography, except at one
site where ß-hCG levels were routinely monitored
and ultrasonography was employed only when
needed. Women with ongoing pregnancies were rec-
ommended suction aspiration. Women with nonvia-
ble pregnancies (eg, sac or other evidence of products
of conception, but no gestational growth and no
cardiac activity on ultrasonography) could opt for
suction aspiration, expectant management, or a sec-
ond misoprostol dose administered by the same route
as the initial dose. If either of the latter two options
was chosen, women were asked to return 7 days later.
If a persistent nonviable pregnancy was diagnosed at
the extended follow-up visit, a suction aspiration was
recommended. Providers also could intervene surgi-
cally if deemed medically necessary (eg, for excessive
bleeding) or at the participant’s request. After expul-
sion was confirmed, women responded to a semi-
structured interview about the experience overall, the
acceptability of the procedure, and adverse effects.
Allocation to study group was determined by
computer-generated assignment concealed in sealed
opaque envelopes. Randomization sequence (using
random blocks of eight and stratified by study center)
and envelopes were prepared by Gynuity Health
Projects staff unrelated to the clinical conduct of the
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study. Envelopes were assigned to study participants
in numerical sequence. Both providers and partici-
pants became aware of group assignment when the
envelopes were opened.
The primary objective of the study was twofold: 1)
to estimate the effectiveness of each regimen among
women with gestations 57 to 63 days since the LMP
and 2) to compare their effectiveness among all
women. In determining the sample size, recruitment
of women in the 57–63 day gestational age group was
a limiting factor, and therefore the sample size calcu-
lation was based on the first stated objective. We
determined that a sample of 105 women in the
gestational age range of 57–63 days was required in
each study arm to be able to estimate efficacy at 93%
with a 95% confidence interval (CI) of5% (assuming
a 5% rate of loss to follow-up). Based on U.S. abortion
clinic statistics, we estimated that 15–20% of all par-
ticipants would fall in the 57–63 day gestational age
group, and anticipated enrolling a total of 1,200
women. With at least 425 women per arm, and
assuming a 95% efficacy for the buccal regimen,11 we
would be able to detect a 5% difference between the
study arms with 80% statistical power at the 95%
confidence level––a difference we considered clini-
cally important for formulating practice guidelines.
Data were analyzed using SPSS 15.0 (SPSS Inc.,
Chicago, IL). An interim analysis was conducted
when approximately 50% of the study sample com-
pleted participation to assess safety. Baseline demo-
graphic variables were compared according to treat-
ment group to test randomization, using the Student t
test or the Mann-Whitney U test for continuous
variables and 2; or Fisher exact test (where cell sizes
were 5 or less) for categorical variables. Normality of
continuous variables was assessed by graphic display.
The primary outcome variable––treatment suc-
cess––was assessed both by per-protocol and inten-
tion-to-treat analyses; because no significant differ-
ences were found using the 2 test, only the per-
protocol analysis is presented. Per-protocol analysis
has been deemed more appropriate for an exploratory
efficacy trial14 and more valuable to clinicians and
clinic managers who want to understand the true
efficacy of the two regimens; moreover, it is com-
monly presented in medical abortion trials.10 In both
analyses, we included in-clinic or telephone follow-up
adequate to determine that a woman’s pregnancy had
been terminated; for per-protocol analysis, adherence
to the regimen was determined according to informa-
tion provided at the follow-up visit. Successful medi-
cal abortion was defined as a complete abortion
without surgical intervention at any point, regardless
of the number of doses of misoprostol taken. For the
final analysis of the primary outcome variable, the
alpha was reduced to 0.0479, as a result of the interim
analysis and according to the O’Brien and Fleming
method.15
Secondary outcome variables were the effect of a
second dose of misoprostol, adverse effects, patient
satisfaction and acceptability of each of the regimens,
adverse effects, and pain; these outcomes were as-
sessed according to treatment group using 2 test or
Fisher exact test. Finally, the effect of gestational age
on primary and secondary outcome variables was
assessed by 2 test for trend, and post-hoc, pair-wise
comparisons were conducted using the Tukey HSD
test, where results were significant. Efficacy within
groups by site was assessed using 2 test or Fisher
exact test. For secondary analyses, two-tailed values
of P.05 were considered significant.
RESULTS
Between September 2006 and May 2007, the study
sites enrolled 966 participants (Fig. 1). Enrollment was
discontinued after 265 women with pregnancies be-
tween 57 and 63 days since the LMP were randomly
assigned, ensuring at least 210 analyzable cases. The
two treatment groups were similar with respect to
education level, marital status, gravidity, gestational
age, and previous abortions, but there was a statisti-
cally significant difference in mean age (25.8 years for
oral compared with 26.7 years for buccal P.02)
(Table 1).
Five participants (0.5%) withdrew from the study
after randomization and 92 (9.5%) were lost-to-follow-
up. The experiences of 847 women were analyzed for
efficacy (Fig. 1). Overall the efficacy after buccal
misoprostol administration was greater than that of
oral administration (96.2% compared with 91.3%,
P.003) (Table 2). An intention-to-treat analysis was
also conducted, which yielded no difference in con-
clusions (96.1%, buccal compared with 91.0%, oral,
P.003, RR 1.06, 95% CI 1.02–1.09). One percent of
the women assigned to buccal misoprostol and 3.5%
of the women assigned to oral misoprostol had a
surgical intervention due to ongoing pregnancy (RR
3.71; P.012). Other reasons for surgical intervention
included persistent nonviable pregnancy or sac (n14),
medical indications (n19), or woman’s request (n1),
none of which varied significantly by study group.
Efficacy did not vary significantly by study group among
all women with gestations 56 days since the LMP or less,
but among women with pregnancies 57–63 days since
the LMP, efficacy was higher after buccal administration
(85.1% compared with 94.8%, RR 0.90; P.015). Fur-
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ther, the frequency of ongoing pregnancy was signifi-
cantly higher in that gestational age group among
women administering misoprostol orally (7.9% com-
pared with 1.7%, RR 4.54; P.029). The success of
buccal administration did not vary significantly with
gestational age (2 for trend 1.776; P.183), although
there was some decline in success with advancing ges-
tational age (Fig. 2). Success after oral administration,
however, was high (96.1%) among women with gesta-
tions 49 days since the LMP or less, but declined to
85.1% among those 57–63 days (P.001).
The frequency of use of a second dose of miso-
prostol at follow-up to treat women with persistent
nonviable pregnancies or uncertain outcomes did not
vary between women in the buccal (n14) and oral
(n12) groups (P.668). Nonetheless, more women
in the buccal group who took a second dose achieved
a successful outcome (92.9% compared with 50.0%,
P.026). After a second dose of misoprostol, the
success rate among women using misoprostol buc-
cally increased by 3.1%, whereas the success rate was
improved by only 1.5% for women in the oral group.
This difference in improved outcome was not statis-
tically significant.
Women reported adverse effects in diaries and in
semistructured interviews at the follow-up visit (Table
3). The differences between what women recorded in
diaries and what they reported in interviews were less
than 10% for all effects except weakness, and approx-
imately 80% of women’s responses were consistent
between the two sources (data not shown). Regardless
of the source of report, the adverse effect profiles of
Fig. 1. Illustration of the flow and
numbers of study participants through
each phase of the study (enrollment,
randomization, follow-up and analysis).
Winikoff. Misoprostol by Mouth in
Medical Abortion. Obstet Gynecol
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each study group were similar. Nausea vomiting, and
diarrhea were reported equally frequently by women
in each group. Fever/chills were also reported about
10% more frequently among women who took miso-
prostol buccally, whether reported in the diary (47.6
compared with 36.1, P.001) or during the exit
interview (41.4% compared with 33.3%, P.020).
Twenty-six (3.0%) women made visits to an emer-
gency room during the study period (14 from the oral
group and 12 from the buccal group), 21 of whom
were not admitted, primarily for pain and bleeding.
Three participants from the buccal group were hos-
pitalized during the study period for reasons that were
unrelated to the study protocol (pulmonary embolus,
ruptured ectopic pregnancy, and right hip pain).
Participants were highly satisfied with the proce-
dure, regardless of the route by which they adminis-
tered misoprostol: 91.9% of women were either satis-
fied or very satisfied (Table 4). Satisfaction decreased
significantly with increasing gestational age in the oral
Table 2. Treatment Outcomes by Study Group and Gestational Age (Days)
Gestational Age
(d) Oral Buccal RR (95% CI)
Success* 91.3* (389/426) (88.2–93.8) 96.2* (405/421) (93.9–97.8) 0.95 (0.92–0.98)
42 or less 97.8 (90/92) (92.4–99.7) 98.7 (75/76) (92.9–100.0) 0.99 (0.93–1.03)
43–49 94.7 (107/113) (88.8–98.0) 96.4 (132/137) (91.7–98.8) 0.93 (0.86–1.00)
50–56 88.8† (95/107) (81.2–94.1) 95.7† (89/93) (89.4–98.8) 0.69 (0.56–1.04)
57–63 85.1* (97/114) (77.2–91.1) 94.8* (109/115) (89.0–98.1) 0.90 (0.82–0.98)
Failure 8.7* (37/426) (6.2–11.8) 3.8* (16/421) (2.2–6.1) 2.29 (1.29–4.04)
Ongoing pregnancy 3.5* (15/426) (2.0–5.7) 1.0* (4/421) (0.3–2.4) 3.71 (1.24–11.07)
42 or less 2.2 (2/92) (0.3–7.6) 1.3 (1/76) (0.0–7.1) 1.65 (0.15–17.87)
43–49 0.9 (1/113) (0.0–4.8) 0.7 (1/137) (0.0–4.0) 1.21 (0.08–19.17)
50–56 2.8 (3/107) (0.6–8.0) 0.0 (0/93) (0.0–3.2) —
57–63 7.9* (9/114) (3.7–14.5) 1.7* (2/115) (0.2–6.1) 4.54 (1.0–20.55)
Medically necessary 2.6 (11/426) (1.3–4.6) 1.9 (8/421) (0.8–3.7) 1.36 (0.55–3.34)
Persistent sac 2.3 (10/426) (1.1–4.3) 1.0 (4/421) (0.3–2.4) 2.47 (0.78–7.82)
Patient request 0.2 (1/426) (0.0–1.3) 0.0 (0/421) (0.0–0.7) —
RR, relative risk; CI, confidence interval.
Data are %, (n/N), or (95% confidence interval), unless otherwise specified.
* P.048, comparing oral and buccal groups.
† P.10, comparing oral and buccal groups.






Age (y)* 25.8 (5.8) 26.7 (6.1)
Educational level
Less than high school 7.6 (33) 7.4 (32)
High school graduate 53.1 (231) 52.3 (227)
University graduate 33.8 (147) 32.0 (139)
Postgraduate degree† 3.9 (17) 6.9 (30)
Unknown 1.6 (7) 1.4 (6)
Currently married 14.1 (61) 16.8 (73)
Gravidity 3 (1–13) 3 (1–11)
Previous abortions 50.5 (219) 46.4 (201)
Gestational age (d) 49.7 (8.3) 49.9 (8.1)




Fig. 2. Illustration of how failure rates and, more specifi-
cally, ongoing pregnancy rates increased with gestational
age, particularly in the group of women that took oral
misoprostol. * Difference between ongoing pregnancy rates
by regimen is statistically significant at 57–63 days since
the LMP (P.029). † Difference between failure rates by
regimen is statistically significant at 57–63 days since the
LMP (P.015).
Winikoff. Misoprostol by Mouth in Medical Abortion. Obstet
Gynecol 2008.
VOL. 112, NO. 6, DECEMBER 2008 Winikoff et al Misoprostol by Mouth in Medical Abortion 1307
group (2 for trend 8.708, P.003) but not in the
buccal group (2 for trend 3.495, P.062). Participant
satisfaction was significantly related to success, re-
gardless of study group (2 136.8, P.001, oral; 2
50.1, P.001, buccal).
Of women having successful abortions, overall
satisfaction was higher among those who took miso-
prostol orally (96.9% compared with 92.8%, P.009).
Among women whose abortions were successful, the
difference in the acceptability of adverse effects be-
tween the study groups was statistically significant,
with more women in the oral group finding the effects
acceptable (78.5% compared with 72.1%, P.037). In
both study groups, pain, the time to completion, and
adverse effects were considered acceptable or very
acceptable to the majority of women (Table 4). In
general, women’s expectations of the procedure were
similar to their experiences, with the majority of
women experiencing the same or less pain (70.7%)
and bleeding (72.5%) than expected. There was no
difference between study groups in expectations of
bleeding, but women were more likely to have less
pain than expected with oral than with buccal admin-
istration (38.6% compared with 29.6%, P.006).
When asked about regimen preference for a future
medical abortion, 93.6% of women in the oral group
responded that they preferred to take misoprostol
orally, whereas only 34.0% of women in the buccal
group would prefer buccal administration. The pri-
mary complaint about the buccal route was a bitter










Satisfaction with procedure 92.6 (389) 91.1 (378) 96.9† (374) 92.8† (372)
Procedure not/slightly difficult 71.2 (299) 70.4 (292) 72.8 (281) 71.3 (286)
Amount bleeding
Less than expected 28.3 (119) 28.9 (120) 25.9 (100) 27.4 (110)
Same as expected 44.0 (185) 43.6 (181) 45.9 (177) 45.1 (181)
More than expected 26.0 (109) 25.3 (105) 26.4 (102) 25.7 (103)
Amount pain
Less than expected 38.6† (162) 29.6† (123) 37.3† (144) 29.2† (117)
Same as expected 34.3 (144) 38.8 (161) 34.7 (134) 39.2 (157)
More than expected 25.7 (108) 29.9 (124) 26.4 (102) 30.2 (121)
Pain acceptable 68.3 (287) 64.8 (269) 68.4 (264) 65.3 (262)
Adverse effects acceptable 76.4 (321) 71.3 (296) 78.5† (303) 72.1† (289)
Time acceptable 83.3 (350) 82.7 (343) 85.5 (330) 84.0 (337)
Data are % (n).
* Satisfied means responded that procedure was either very satisfactory or satisfactory; acceptable means that women reported adverse
effects, pain, or time of procedure was either acceptable or very acceptable.
† P.05 comparing oral and buccal groups.
Table 3. Adverse Effects (% Reporting Ever Experiencing)*
Adverse Effect








(n415) RR (95% CI) P
None 2.6 (11) 4.9 (21) 1.67 (0.99–2.83) .132 7.1 (30) 8.0 (33) 0.90 (0.56–1.46) .680
Nausea 68.5 (285) 75.1 (311) 0.92 (0.84–1.01) .067 63.6 (267) 66.0 (274) 0.97 (0.88–1.07) .559
Vomiting 43.5 (181) 47.6 (197) 0.92 (0.79–1.07) .228 39.5 (166) 40.2 (167) 0.99 (0.84–1.17) .901
Diarrhea 38.7 (161) 43.0 (178) 0.91 (0.77–1.07) .257 35.0 (147) 33.7 (140) 1.05 (0.87–1.26) .646
Fever/chills 36.1 (150) 47.6 (197) 0.76 (065–0.90) .001 33.3 (140) 41.4 (172) 0.81 (0.68–0.97) .020
Headache 38.5 (160) 41.1 (170) 0.95 (0.80–1.12) .517 31.0 (130) 34.0 (141) 0.92 (0.75–1.12) .393
Dizziness 37.5 (156) 39.4 (163) 0.96 (0.81–1.14) .658 29.8 (125) 32.8 (136) 0.91 (0.75–1.12) .389
Weakness 53.6 (223) 58.0 (240) 0.93 (0.83–1.06) .274 42.9 (180) 45.1 (187) 0.96 (0.82–1.12) .588
RR, relative risk; CI, confidence interval.
Data are % (n) unless otherwise specified.
* Responses were consistent between reports on diaries and in exit interviews for 83% of women reporting nausea, 87% reporting diarrhea,
83% reporting dizziness, 83% reporting headache, 79% reporting weakness, and 85% reporting fever/chills.
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and chalky taste of the misoprostol, mentioned by
24% of women who administered it that way.
DISCUSSION
Our study demonstrates that, after 200 mg mifepris-
tone, a dose of 800 mcg buccal misoprostol is more
effective at terminating pregnancy than an 800 mcg
oral dose. The buccal regimen is superior to the oral
regimen between 57 days and 63 days since the LMP,
with a trend over the entire gestational age range
toward superiority between 49 days and 56 days since
the LMP. Our results on the performance of the 800
mcg oral misoprostol regimen corroborate previous
research that demonstrates a total efficacy of 90% or
greater using oral regimens through 63 days since the
LMP8,10,16–20 and also corroborates that with increas-
ing gestational age, success decreases and ongoing
pregnancies rise significantly.9,16,17,21 However, of the
studies of 800 mcg oral misoprostol, one was termi-
nated early due to low tolerance of adverse effects and
reported outcomes in only 27 women.9 In the other
study, the failure rate among women 57–63 days
since the LMP who took misoprostol orally was only
two percentage points higher than among those who
administered it vaginally (9.8% compared with 7.8%;
RR 2.8, 95% CI 1.3–5.8),10 a difference that may not
be clinically relevant.
Our data also show that efficacy with buccal
administration also decreases slightly with increasing
gestational age (Table 2). Similar declines in efficacy
may be observable regardless of route in early med-
ical abortion.9,10,16,22,23 There are three published trials
using buccal misoprostol for pregnancy termina-
tion,11,24,25 one of which used methotrexate, not mife-
pristone,25 another was a pilot, noncomparative trial,24
and the last of which tested the regimen only through
56 days since the LMP.11 Our study demonstrates
clearly that buccal misoprostol 800 mcg after mife-
pristone 200 mg is appropriate for use between 57–63
days since the LMP, whereas oral misoprostol 800
mcg is not as effective.
Differences in pharmacokinetics between oral
and buccal routes offer one possible explanation for
the different success rates, because the rapid peak in
serum levels after oral use has been observed to result
in increased uterine tone but not sustained uterine
contractions. In contrast, regular and sustained uter-
ine contractility has been documented after buccal as
well as vaginal administration.13
Several large randomized clinical trials suggest
that a repeated misoprostol dose may have a “level-
ing” effect on success among regimens.10,16 A leveling
effect was not observed in our study where use of
additional misoprostol doses did not differ between
study groups. In fact, the effect of a second dose
among women who received it was a 1.5% increment
in success for the oral regimen and 3.1% increment
for the buccal route, widening the difference in effi-
cacy between the routes.
Adverse effects were acceptable to women in
both study groups and did not seem to affect overall
satisfaction with the method, which was very high.
Moreover, adverse effects did not vary significantly
by study group, with the exception of more reports of
fever/chills among those who took misoprostol buc-
cally, but which were not judged clinically important.
The adverse-effects profile in the buccal group was
quite similar to that published by Middleton et al.11
Despite claims that oral misoprostol leads to more
gastrointestinal adverse effects (vomiting and diar-
rhea)9,26 and the fact that our oral dose was higher
than that used in some studies, we observed no
differences in such effects between oral and buccal
administration.
Clinical practices, including the timing and length
of follow-up and propensity to intervene, have an
important effect on observed differences in success
rates in the published literature as well as in practice.
A published meta-analysis and another case series
have confirmed that provider practice may affect
method success.27,28 Clinicians in our study were
aware of a woman’s assigned regimen, and it is
possible that this knowledge inadvertently influenced
patient management. However, the overall differ-
ences in the reasons for surgical intervention were
neither large nor significant, with the exception of
ongoing pregnancies, the diagnosis of which is not as
subject to provider bias.
The consideration of provider practice is partic-
ularly relevant because most of the mifepristone–
misoprostol regimens tested in randomized trials are
highly effective (greater than 90% overall efficacy).
Moreover, management disparities may help to ex-
plain inconsistencies among randomized controlled
trials, especially those done in one or only a few sites.
The effect of provider practices may be unavoidable,
costly to measure, and difficult to interpret, but if trial
results should guide real-world practice, there is ben-
efit to a protocol that does not overregulate clinical
management.
In addition to oral and buccal, sublingual admin-
istration is another possible nonvaginal route of drug
administration in medical abortion. The two random-
ized trials that had reported on the sublingual route
through 63 days since the LMP at the time we
initiated our study22,23 examined use in a total of only
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169 women. These data were insufficient to assume
that sublingual administration was a more promising
route than buccal misoprostol, which had already
been demonstrated to be at least as effective as
vaginal misoprostol through 56 days since the LMP.11
The sublingual route remains an alternative that
warrants further investigation.
The findings of our research are important for
expanding the availability of medical abortion to
women with pregnancies beyond 56 days of gestation
where providers or women are reluctant to use vagi-
nal misoprostol. Our results support the offer of a
highly effective, safe, and acceptable nonvaginal reg-
imen for early termination of pregnancy.
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